Sanofi has licensed Kiadis’s modified K-NK cell therapies to combine with its anti-CD38...
- Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
- Access to Covid-19 vaccines: MSF’s concerns about Gavi’s COVAX AMC
- Access to Covid-19 vaccines: deep dive into Gavi’s COVAX AMC
- Investing in late-stage companies: Forbion closes Growth Fund at €185m
- Exploring the promise of DUBs: Mission teams up with Pfizer
Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
Sanofi has licensed Kiadis’s modified K-NK cell therapies to combine with its anti-CD38 antibody Sarclissa in multiple myeloma. How could this combination approach improve treatment outcomes for these blood cancer patients?
Access to Covid-19 vaccines: MSF’s concerns about Gavi’s COVAX AMC
Gavi’s COVAX Facility and associated AMC aims to facilitate fair access to Covid-19 vaccines. However, global health charity MSF has apprehensions about various elements of the initiative, primarily linked to its view of Gavi’s previous AMC for PCVs. Let’s look deeper into MSF’s worries and its alternative recommendations.
Access to Covid-19 vaccines: deep dive into Gavi’s COVAX AMC
The only way the Covid-19 pandemic can be brought to an end is if everyone across the world has access to the right diagnostics, treatments, and importantly, vaccines. So the WHO launched the ACT-Accelerator; heading up its vaccine pillar is Gavi, which has created a COVAX Facility and advanced market commitment (AMC) mechanism for Covid-19 vaccines. How does this facility and AMC aim to help ensure equitable access to Covid-19 vaccines, once approved?
Investing in late-stage companies: Forbion closes Growth Fund at €185m
Forbion has closed its new Growth Opportunities Fund at €185m, but it is hoping to raise a further €65m before the fund is completed this year. This fund will invest in promising late-stage companies, an underserved market, with the support of its expert Advisory Group.
Exploring the promise of DUBs: Mission teams up with Pfizer
Pfizer Ventures has expanded its relationship with DUB-focused Mission Therapeutics by leading a $15m funding round. The pharma giant’s core company has also signed a scientific partnership to validate promising DUB drug targets. What potential do DUBs have in treating disease?
Twist partners with Takeda on antibody drug discovery
Takeda has signed an antibody drug discovery agreement with Twist Bioscience. The pair will use Twist’s synthetic ‘Library of Libraries’ to discover and validate antibody candidates for a range of diseases. How can synthetic biology accelerate antibody drug discovery?
Off-the-shelf NK cell therapies: Artiva closes $78m Series A round
Artiva is working on bringing off-the-shelf NK cell therapies to cancer patients, supported by the manufacturing expertise of GC LabCell. To fund Artiva’s progression of three lead candidates to clinical trials, the company has raised $78m in a Series A round.
Tackling the next health crisis: pharma launches $1bn AMR Action Fund
Covid-19 is not the only public health threat facing the world. Drug-resistant bacterial infections have the potential to kill 10 million people a year by 2050 unless there are serious efforts to overcome the market failure in antibiotics development. IFPMA has brought together over 20 major pharma companies and public institutions to launch a $1bn fund to support antibiotic R&D.
Eir Ventures launches to unlock the potential of the Nordics
Supported by three prestigious investment companies and the EU's EIF, Eir Ventures is a Nordic-based venture company with €76m to invest in promising ideas from regional universities and incubators. How will Eir Ventures help to tap into the largely overlooked potential of the Nordic countries in life sciences?
Intellectual property in the time of Covid-19
Governments have been waiving common Intellectual Property laws in pursuit of a treatment for Covid-19, overriding patent protections and allowing sales of generic drugs. This is a concerning move for pharma companies struggling to navigate unclear rules, but could it change the R&D landscape forever? Abi Millar fins out more about IP during the Covid-19 crisis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.